Last updated on March 2019

Safety Tolerability Pharmacokinetics and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Brief description of study

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease

Detailed Study Description

Allocation: RandomizedEndpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment

Clinical Study Identifier: NCT03186989

Contact Investigators or Research Sites near you

Start Over

Anne Lithonius

Clinical Research Services Turku CRST
Turku, Finland
  Connect »

Ionis Pharmaceuticals

Charite - Universitaetsmedizin Berlin Campus Mitte
Berlin, Germany
  Connect »

Barbara Kaminski

St Josef Hospital
Bochum, Germany
  Connect »

Ralf Bodenschatz

MVZ Mittweida Gbr
Mittweida, Germany
  Connect »

Christine Von Arnim

Universittsklinikum Ulm
Ulm, Germany
  Connect »

Peter P De Deyn

Faculty Medical Sciences UMCG Neurology
Groningen, Netherlands
  Connect »

Anne Borjesson-Hanson

Karolinska University Hospital Huddinge
Stockholm, Sweden
  Connect »

Richard Fitzgerald

Royal Liverpool University Hospital
Liverpool, United Kingdom
  Connect »

Cath Mummery

University College London Hospitals NHS Foundation Trust
London, United Kingdom
  Connect »

Daniel Blackburn

Sheffield Institute for Translational Neuroscience (SITraN)
Sheffield, United Kingdom
  Connect »

Anja Schneider

Deutsches Zentrum f r Neurodegenerative Erkrankungen (DZNE)
Bonn, Germany
  Connect »

Angela Genge

Montreal Neurological Hospital
Montréal, Canada
  Connect »

Anne Borjesson-Hanson

Mölndal, Sweden
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.